
Emergent BioSolutions (EBS) Stock Forecast & Price Target
Emergent BioSolutions (EBS) Analyst Ratings
Bulls say
Emergent BioSolutions is benefiting from durable government-backed demand for its biodefense portfolio, highlighted by a roughly $24M BARDA contract modification for CYFENDUS and an earlier delivery order of up to $21.5M for BioThrax, reinforcing the company’s role in anthrax preparedness and national security. Its outlook is further supported by stronger financial discipline, including a $75M senior note repurchase that cut outstanding notes to about $364.7M and leaves total debt near $515M, while cash is expected to exceed $180M by 3Q26 and an additional $50M remains available under its revolver. Operationally, the restructuring plan targeting about $40M of annualized savings, alongside commercial progress for NARCAN, ACAM2000, and other products, suggests improving efficiency and multiple growth levers across its U.S.-focused revenue base.
Bears say
Emergent BioSolutions is viewed negatively because its valuation support is weak, with a DCF using an 11% discount rate and 1% terminal decline producing only about $872M in enterprise value and $600M in firm value when projected mid-2027 cash and debt are included. The outlook is pressured by material execution risks, including faster-than-expected NARCAN franchise erosion from generic competition, limited visibility into winning additional MCM government stockpiling and procurement contracts, and uncertainty around approvals for key products. The company also faces potential medium- to long-term dilution risk, and the impairment of long-lived assets signals further strain on asset quality and future earnings power.
This aggregate rating is based on analysts' research of Emergent BioSolutions and is not a guaranteed prediction by Public.com or investment advice.
Emergent BioSolutions (EBS) Analyst Forecast & Price Prediction
Start investing in Emergent BioSolutions (EBS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Emergent BioSolutions (EBS) Forecast
Emergent BioSolutions (EBS) Analyst Forecast & Price Prediction
Start investing in Emergent BioSolutions (EBS)
Order type
Buy in
Order amount
Est. shares
0 shares